probucol has been researched along with Hyperlipemia in 123 studies
Probucol: A drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. (From Martindale, The Extra Pharmacopoeia, 30th ed, p993).
probucol : A dithioketal that is propane-2,2-dithiol in which the hydrogens attached to both sulfur atoms are replaced by 3,5-di-tert-butyl-4-hydroxyphenyl groups. An anticholesteremic drug with antioxidant and anti-inflammatory properties, it is used to treat high levels of cholesterol in blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia." | 9.06 | A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990) |
| "In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome." | 7.70 | Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. ( Fiehn, W; Kohl, B; Michalk, D; Minor, T; Müller-Wiefel, DE; Querfeld, U; Schärer, K, 1999) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 7.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome." | 7.67 | Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. ( Asaka, M; Fujita, M; Iida, H; Izumino, K; Nishino, A; Sasayama, S, 1987) |
| "High-fat pancreatitis and hyperlipidemia refer to disorders of blood lipid metabolism caused by abnormally elevated blood lipids, and are risk factors for high-risk diseases such as atherosclerosis, coronary heart disease, and cerebral infarction." | 5.62 | Study on the Mechanism of Probucol Nanosuspension on Hyperlipidemic Pancreatitis and Regulation of Blood Lipid Function. ( Jiang, X; Wang, X; Wu, Z, 2021) |
| "Hypercholesterolemic patients with coronary artery disease were randomized to three groups and received study drugs for 3 years: the control with statin alone; the probucol group with statin and probucol; and the combo group with statin, probucol, and cilostazol." | 5.41 | Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study. ( Ge, J; Kang, HJ; Kim, CH; Kim, MH; Kim, SH; Oh, BH; Park, JE; Sung, J, 2021) |
| "Nephrotic syndrome accompanies hyperlipidemia for which HMG-CoA reductase inhibitors are mainly used." | 5.31 | [Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]. ( Aoki, M; Futami, T; Inui, K; Muso, E; Ono, T; Osawa, R; Wakasugi, H; Yoshimoto, M, 2001) |
| "Probucol is shown to be a better accelerator for lipid clearance in triton hyperlipidemia than clofibrate." | 5.27 | Effect of probucol on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Shridhar, DR; Thapar, GS, 1985) |
| "A multicenter study was undertaken to compare the effects of lovastatin (given in 4 different dosage regimens) and probucol in patients with severe primary hypercholesterolemia." | 5.06 | A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV. ( , 1990) |
| "We describe that high-dose methylprednisolone (20 mg/kg) can induce multifocal osteonecrosis (ON) in conjunction with thrombocytopenia, hypofibrinogenemia, and hyperlipemia." | 4.84 | [Animal models for steroid-induced osteonecrosis]. ( Iwamoto, Y; Miyanishi, K; Motomura, G; Nishida, K; Sueishi, K; Yamamoto, T, 2007) |
| " In this study, serum lipid profiles and heart protective effects were evaluated in high fat diet (HFD) induced hyperlipidemia in aging rats treated with APPH (15, 45 and 75 mg/kg/day) and probucol (500 mg/kg/day)." | 3.81 | The Heart Protection Effect of Alcalase Potato Protein Hydrolysate Is through IGF1R-PI3K-Akt Compensatory Reactivation in Aging Rats on High Fat Diets. ( Chang, CH; Chiang, WD; Hu, WS; Huang, CY; Lin, WT; Pai, P; Ting, WJ; Yeh, YL, 2015) |
| "In a prospective, uncontrolled multicenter study, we have evaluated the effects of probucol on hyperlipidemia, proteinuria, and glomerular filtration rate (GFR) in hyperlipidemic children with persistent nephrotic syndrome." | 3.70 | Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study. ( Fiehn, W; Kohl, B; Michalk, D; Minor, T; Müller-Wiefel, DE; Querfeld, U; Schärer, K, 1999) |
| "Hyperlipidemia associated with nephrotic syndrome was treated with probucol and the changes in plasma lipoprotein lipid concentration and urinary protein excretion were examined in puromycin aminonucleoside-induced nephrotic rats." | 3.68 | The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats. ( Hirano, T; Mamo, JC; Nagano, S; Sugisaki, T, 1991) |
| "We have evaluated the effect of the antihyperlipidemic agent probucol on hyperlipidemia in patients with nephrotic syndrome." | 3.67 | Effect of probucol on hyperlipidemia in patients with nephrotic syndrome. ( Asaka, M; Fujita, M; Iida, H; Izumino, K; Nishino, A; Sasayama, S, 1987) |
| "Probucol is a potent antioxidant and reduces tendon xanthomas in familial hypercholesterolemia patients despite reduction of high-density lipoprotein (HDL)-cholesterol (HDL-C)." | 3.01 | Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE). ( Arai, H; Bujo, H; Doi, Y; Fukushima, M; Ishibashi, T; Kita, T; Masuda, D; Matsuzaki, M; Matsuzawa, Y; Nakagawa, S; Ohama, T; Saito, Y; Tanabe, K; Yamashiro, K; Yamashita, S; Yanagi, K, 2021) |
| "Probucol has a major, and vitamin E a minor, effect on LDL resistance to oxidation but neither compound appears to alter forearm vascular responses in vivo." | 2.67 | The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans. ( Brennan, GM; Bruce, I; Johnston, GD; McDowell, IF; McEneny, J; McVeigh, GE; Nicholls, DP; Trimble, ER; Young, IS, 1994) |
| "7%) on probucol reported mild to moderately severe side-effects, mainly gastro-intestinal, but in no case was treatment interrupted, although benzafibrate dosage was temporarily reduced." | 2.66 | Comparative study of bezafibrate and probucol in hyperlipidaemia. ( González, G; Páez Moreno, JP, 1989) |
| " In 32 patients with Type II HL and 12 with Type IIB HL, statistically significant reduction in mean serum cholesterol levels occurred within two weeks and persisted throughout two years of therapy at constant dosage (500 mg." | 2.64 | Effect of probucol in hyperlipidemic patients during two years of administration. ( Parsons, WB, 1978) |
| "When probucol was added to the diet of the responders, their plasma cholesterol level was lowered a further 13%." | 2.64 | Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia. ( Davignon, J; DuBreuil-Quidoz, S; Huang, YS; LeLorier, J; Lussier-Cacan, S, 1977) |
| "Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease." | 2.39 | Hyperlipidemia: perspectives in diagnosis and treatment. ( Gotto, AM; Yeshurun, D, 1995) |
| "Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy." | 2.37 | Contemporary recommendations for evaluating and treating hyperlipidemia. ( Perry, RS, 1986) |
| "High-fat pancreatitis and hyperlipidemia refer to disorders of blood lipid metabolism caused by abnormally elevated blood lipids, and are risk factors for high-risk diseases such as atherosclerosis, coronary heart disease, and cerebral infarction." | 1.62 | Study on the Mechanism of Probucol Nanosuspension on Hyperlipidemic Pancreatitis and Regulation of Blood Lipid Function. ( Jiang, X; Wang, X; Wu, Z, 2021) |
| "Atherosclerosis is a multifactorial disease with several mechanisms participating in its manifestation." | 1.37 | Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents. ( Katselou, MG; Kourounakis, AP; Matralis, AN; Nikitakis, A, 2011) |
| "The probucol and DR groups were fed the same diet as the control group but with the addition of 100 mg probucol/kg chow and 200 mg DR/kg chow, respectively." | 1.33 | Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome. ( Chang, WC; Tseng, YH; Wu, CH; Wu, KY; Yu, YM, 2005) |
| "Ellagic acid is a phenolic compound present in fruits and nuts, and has been found to have antioxidative property." | 1.33 | Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid. ( Chang, WC; Chiang, SY; Wu, CH; Yu, YM, 2005) |
| "Probucol is a lipid-lowering agent with an antioxidant effect; however, its influence on the liver remains unclear." | 1.31 | Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study. ( Aktuna Keskil, Z; Aşan, E; Korkusuz, P; Ugur, Y; Uluoglu, C, 2002) |
| "Nephrotic syndrome accompanies hyperlipidemia for which HMG-CoA reductase inhibitors are mainly used." | 1.31 | [Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome]. ( Aoki, M; Futami, T; Inui, K; Muso, E; Ono, T; Osawa, R; Wakasugi, H; Yoshimoto, M, 2001) |
| "Quercetin treated animals did not show increased oxidation of LDL (and VLDL in rabbits) and cholesterol levels were not decreased." | 1.30 | Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits. ( Lauridsen, ST; Mortensen, A, 1999) |
| "This appears to be due both to reduced coronary atherosclerosis and to a different, more stable type of atherosclerotic disease in this animal model." | 1.30 | Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet. ( Bräsen, JH; Harsch, M; Niendorf, A, 1998) |
| " Thus, long-term administration appears to suppress the progression of atherosclerotic vascular disease in this animal model." | 1.30 | Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits. ( Aoki, K; Hori, M; Hoshida, S; Igarashi, J; Kuzuya, T; Yamashita, N, 1997) |
| "A decision to treat hyperlipidemias would be based on the assumption that such disorders lead to accelerated atherogenesis and ultimately to cardiac dysfunction." | 1.30 | Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation. ( Kesten, S; Maurer, J; Mayne, L; Scavuzzo, M, 1997) |
| "Probucol was without effect on this index of in vivo LDL oxidation." | 1.29 | Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits. ( Demacker, PN; Kleinveld, HA; Stalenhoef, AF, 1994) |
| "Probucol treatment significantly reduced the lipid concentration in all major lipoproteins, significantly reduced proteinuria and increased plasma albumin concentration." | 1.28 | Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis. ( Hirano, T; Morohoshi, T, 1992) |
| "Probucol treatment resulted in a change not only in the size but also the composition of lesions." | 1.28 | Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques. ( Cho, M; Kita, T; Matsuzawa, Y; Nagano, Y; Nakamura, T; Ueda, Y, 1992) |
| " In addition to survey in 6,002 patients, the effect on regression of xanthomas and safety in long-term administration of over one year was investigated in 44 and 142 patients, respectively." | 1.28 | Post-marketing surveillance of probucol (Sinlestal) in Japan. ( Kosasayama, A; Okada, S; Yoshida, M, 1992) |
| "1." | 1.28 | The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits. ( Daugherty, A; Schonfeld, G; Zweifel, BS, 1991) |
| "Probucol has been used as a lipid-lowering agent for over 10 years." | 1.28 | Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect? ( Beisiegel, U; Finckh, B; Niendorf, A; Rath, M, 1991) |
| "Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia." | 1.27 | Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986) |
| "Oral carnitine has been reported to have a lipid-lowering effect with concomitant elevation of high density lipoprotein cholesterol (HDL-C) levels in normo- and hyperlipidemic individuals." | 1.27 | Plasma carnitine and lipid-lowering drugs. ( Davignon, J; Nestruck, AC; Pande, SV, 1985) |
| "Probucol is shown to be a better accelerator for lipid clearance in triton hyperlipidemia than clofibrate." | 1.27 | Effect of probucol on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Shridhar, DR; Thapar, GS, 1985) |
| " Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention." | 1.27 | Adverse effects of the treatment for hyperlipidemia. ( Malinow, MR, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 43 (34.96) | 18.7374 |
| 1990's | 46 (37.40) | 18.2507 |
| 2000's | 24 (19.51) | 29.6817 |
| 2010's | 6 (4.88) | 24.3611 |
| 2020's | 4 (3.25) | 2.80 |
| Authors | Studies |
|---|---|
| Matralis, AN | 2 |
| Katselou, MG | 1 |
| Nikitakis, A | 1 |
| Kourounakis, AP | 2 |
| Ladopoulou, E | 1 |
| Yamashita, S | 2 |
| Arai, H | 1 |
| Bujo, H | 1 |
| Masuda, D | 2 |
| Ohama, T | 1 |
| Ishibashi, T | 1 |
| Yanagi, K | 1 |
| Doi, Y | 1 |
| Nakagawa, S | 2 |
| Yamashiro, K | 1 |
| Tanabe, K | 1 |
| Kita, T | 4 |
| Matsuzaki, M | 1 |
| Saito, Y | 2 |
| Fukushima, M | 1 |
| Matsuzawa, Y | 3 |
| Kang, HJ | 1 |
| Kim, MH | 1 |
| Sung, J | 1 |
| Kim, SH | 1 |
| Kim, CH | 1 |
| Park, JE | 1 |
| Ge, J | 1 |
| Oh, BH | 1 |
| Wu, Z | 1 |
| Wang, X | 1 |
| Jiang, X | 1 |
| Ma, Q | 1 |
| Han, Y | 1 |
| Chen, C | 1 |
| Cao, Y | 1 |
| Wang, S | 1 |
| Shen, W | 1 |
| Zhang, H | 1 |
| Li, Y | 1 |
| van Dongen, MA | 1 |
| He, B | 1 |
| Yu, M | 1 |
| Xu, L | 1 |
| Banaszak Holl, MM | 1 |
| Liu, G | 1 |
| Zhang, Q | 1 |
| Qi, R | 1 |
| Hu, WS | 1 |
| Ting, WJ | 1 |
| Chiang, WD | 1 |
| Pai, P | 1 |
| Yeh, YL | 1 |
| Chang, CH | 1 |
| Lin, WT | 1 |
| Huang, CY | 1 |
| Jung, YS | 1 |
| Park, JH | 1 |
| Kim, H | 1 |
| Kim, SY | 1 |
| Hwang, JY | 1 |
| Hong, KW | 1 |
| Bae, SS | 1 |
| Choi, BT | 1 |
| Lee, SW | 1 |
| Shin, HK | 1 |
| Yasuda, G | 1 |
| Ando, D | 1 |
| Hirawa, N | 1 |
| Umemura, S | 1 |
| Korkusuz, P | 1 |
| Ugur, Y | 1 |
| Aşan, E | 1 |
| Aktuna Keskil, Z | 1 |
| Uluoglu, C | 1 |
| Horiuchi, K | 1 |
| Takatori, A | 1 |
| Inenaga, T | 1 |
| Ohta, E | 1 |
| Yamanouchi, J | 1 |
| Kawamura, S | 1 |
| Ishii, Y | 1 |
| Kyuwa, S | 1 |
| Yoshikawa, Y | 2 |
| Asberg, A | 1 |
| Gotto, AM | 3 |
| Nomura, S | 1 |
| Takahashi, N | 1 |
| Inami, N | 1 |
| Kajiura, T | 1 |
| Yamada, K | 1 |
| Nakamori, H | 1 |
| Tsuda, N | 1 |
| Wenke, K | 1 |
| Ohtani, K | 1 |
| Egashira, K | 1 |
| Finné Nielsen, IL | 1 |
| Elbøl Rasmussen, S | 1 |
| Mortensen, A | 2 |
| Ravn-Haren, G | 1 |
| Ma, HP | 1 |
| Knuthsen, P | 1 |
| Hansen, BF | 1 |
| McPhail, D | 1 |
| Freese, R | 1 |
| Breinholt, V | 1 |
| Frandsen, H | 1 |
| Dragsted, LO | 1 |
| Chang, WC | 2 |
| Yu, YM | 2 |
| Wu, CH | 2 |
| Tseng, YH | 1 |
| Wu, KY | 1 |
| Chiang, SY | 1 |
| Tanimoto, T | 1 |
| Yamamoto, T | 1 |
| Miyanishi, K | 1 |
| Motomura, G | 1 |
| Nishida, K | 1 |
| Iwamoto, Y | 1 |
| Sueishi, K | 1 |
| Ayaori, M | 1 |
| Ogura, M | 1 |
| Kusuhara, M | 1 |
| Fukumoto, Y | 1 |
| Shimokawa, H | 1 |
| Nash, DT | 2 |
| Bertolami, MC | 1 |
| Bertolami, V | 1 |
| Hunninghake, DB | 1 |
| Nestel, PJ | 1 |
| Ng, AS | 1 |
| Johan, A | 1 |
| Quek, SS | 1 |
| Tan, IK | 1 |
| Melico-Sylvestre, AA | 1 |
| Jacotot, B | 1 |
| Buxtorf, JC | 1 |
| Beaumont, V | 1 |
| Beaumont, JL | 1 |
| Giannini, SD | 3 |
| Forti, N | 3 |
| Ziliotto, EE | 1 |
| Samuel, P | 1 |
| Tillement, JP | 1 |
| Albengres, E | 1 |
| Choisy, H | 1 |
| Millart, H | 1 |
| Yeshurun, D | 1 |
| Yamasaki, K | 1 |
| Fiorini, F | 1 |
| Patrone, E | 1 |
| Castelluccio, A | 1 |
| McDowell, IF | 1 |
| Brennan, GM | 1 |
| McEneny, J | 1 |
| Young, IS | 1 |
| Nicholls, DP | 2 |
| McVeigh, GE | 1 |
| Bruce, I | 1 |
| Trimble, ER | 1 |
| Johnston, GD | 1 |
| Kuo, PT | 1 |
| Kleinveld, HA | 2 |
| Demacker, PN | 2 |
| Stalenhoef, AF | 2 |
| Malloy, MJ | 1 |
| Kane, JP | 1 |
| Lankin, VZ | 2 |
| Revenko, VM | 2 |
| Lupanov, VP | 3 |
| Tikhaze, AK | 2 |
| Liakishev, AA | 1 |
| Kukharchuk, VV | 1 |
| Hijmans, AG | 1 |
| Shinomiya, M | 1 |
| Shirai, K | 1 |
| Yoshida, S | 1 |
| Betteridge, DJ | 1 |
| Dodson, PM | 1 |
| Durrington, PN | 1 |
| Hughes, EA | 1 |
| Laker, MF | 1 |
| Rees, JA | 1 |
| Seymour, CA | 1 |
| Thompson, GR | 1 |
| Winder, AF | 1 |
| Ozawa, K | 1 |
| Mann, WA | 1 |
| Windler, E | 1 |
| Beil, FU | 1 |
| Greten, H | 1 |
| Bravo, E | 1 |
| Ortu, G | 1 |
| Rivabene, R | 1 |
| Santini, MT | 1 |
| Cantafora, A | 1 |
| Kesten, S | 1 |
| Mayne, L | 1 |
| Scavuzzo, M | 1 |
| Maurer, J | 1 |
| Hoshida, S | 1 |
| Yamashita, N | 1 |
| Igarashi, J | 1 |
| Aoki, K | 1 |
| Kuzuya, T | 1 |
| Hori, M | 1 |
| Mikhin, VP | 1 |
| Itoh, H | 1 |
| Komori, K | 1 |
| Okazaki, J | 1 |
| Mawatari, K | 1 |
| Kawasaki, K | 1 |
| Kuma, S | 1 |
| Eguchi, D | 1 |
| Sugimachi, K | 1 |
| Oshima, R | 1 |
| Ikeda, T | 1 |
| Watanabe, K | 1 |
| Itakura, H | 2 |
| Sugiyama, N | 1 |
| Davignon, J | 4 |
| Bräsen, JH | 1 |
| Harsch, M | 1 |
| Niendorf, A | 2 |
| Leng, GC | 1 |
| Price, JF | 1 |
| Jepson, RG | 1 |
| Lauridsen, ST | 1 |
| Querfeld, U | 1 |
| Kohl, B | 1 |
| Fiehn, W | 1 |
| Minor, T | 1 |
| Michalk, D | 1 |
| Schärer, K | 1 |
| Müller-Wiefel, DE | 1 |
| Witting, P | 1 |
| Pettersson, K | 1 |
| Ostlund-Lindqvist, AM | 1 |
| Westerlund, C | 1 |
| Wâgberg, M | 1 |
| Stocker, R | 1 |
| Allott, CP | 1 |
| Barry, CD | 1 |
| Bramley, J | 1 |
| John, NW | 1 |
| Mellor, PM | 1 |
| Thomson, DS | 1 |
| Reilly, CF | 1 |
| Shi, A | 1 |
| Yoshinari, M | 1 |
| Iino, K | 1 |
| Wakisaka, M | 1 |
| Iwase, M | 1 |
| Fujishima, M | 1 |
| El-Swefy, S | 1 |
| Schaefer, EJ | 1 |
| Seman, LJ | 1 |
| van Dongen, D | 1 |
| Sevanian, A | 1 |
| Smith, DE | 1 |
| Ordovas, JM | 1 |
| El-Sweidy, M | 1 |
| Meydani, M | 1 |
| Batra, S | 1 |
| Srivastava, S | 1 |
| Singh, K | 1 |
| Chander, R | 1 |
| Khanna, AK | 1 |
| Bhaduri, AP | 1 |
| Anikin, VV | 1 |
| Savin, VV | 1 |
| Razygraev, RA | 1 |
| Titov, VN | 1 |
| Zaĭtseva, TM | 1 |
| Djahansouzi, S | 1 |
| Braesen, JH | 1 |
| Koenig, K | 1 |
| Beisiegel, U | 2 |
| Kontush, A | 1 |
| Yagyu, H | 1 |
| Ogaki, S | 1 |
| Matsushima, T | 1 |
| Hirano, T | 4 |
| Yoshino, G | 1 |
| Kimura, Y | 1 |
| Uchiyama, S | 1 |
| Wakasugi, H | 1 |
| Yoshimoto, M | 1 |
| Aoki, M | 1 |
| Osawa, R | 1 |
| Futami, T | 1 |
| Ono, T | 1 |
| Muso, E | 1 |
| Inui, K | 1 |
| Murphy, BF | 1 |
| LeLorier, J | 1 |
| DuBreuil-Quidoz, S | 1 |
| Lussier-Cacan, S | 1 |
| Huang, YS | 1 |
| Heel, RC | 1 |
| Brogden, RN | 1 |
| Speight, TM | 1 |
| Avery, GS | 1 |
| Parsons, WB | 1 |
| Diament, J | 1 |
| Fleischmajer, R | 1 |
| Miettinen, TA | 2 |
| Paterson, JR | 1 |
| Rumley, AG | 1 |
| Oldroyd, KG | 1 |
| Tait, GW | 1 |
| Smellie, WS | 1 |
| Packard, CJ | 1 |
| Shepherd, J | 1 |
| Lorimer, AR | 1 |
| Grundy, SM | 3 |
| Morohoshi, T | 1 |
| Nagano, Y | 3 |
| Nakamura, T | 1 |
| Cho, M | 1 |
| Ueda, Y | 1 |
| Kosasayama, A | 1 |
| Yoshida, M | 1 |
| Okada, S | 1 |
| Mimura, K | 1 |
| Yukawa, S | 1 |
| Avogaro, P | 1 |
| Cazzolato, G | 1 |
| Bittolo-Bon, G | 1 |
| Mamo, JC | 2 |
| Nagano, S | 1 |
| Sugisaki, T | 2 |
| Daugherty, A | 1 |
| Zweifel, BS | 1 |
| Schonfeld, G | 1 |
| Finckh, B | 1 |
| Rath, M | 1 |
| D'Amico, G | 1 |
| Gentile, MG | 1 |
| Kesäniemi, YA | 1 |
| Noma, A | 1 |
| Maeda, S | 1 |
| Okuno, M | 1 |
| Abe, A | 1 |
| Muto, Y | 1 |
| Ohnami, K | 1 |
| Páez Moreno, JP | 1 |
| González, G | 1 |
| Mori, Y | 1 |
| Wada, H | 1 |
| Deguchi, K | 1 |
| Shirakawa, S | 1 |
| Huttunen, JK | 1 |
| Naukkarinen, V | 1 |
| Strandberg, T | 1 |
| Vanhanen, H | 1 |
| Dereviacki, BE | 1 |
| Naito, HK | 1 |
| Yokode, M | 1 |
| Ishii, K | 1 |
| Kume, N | 1 |
| Narumiya, S | 1 |
| Kawai, C | 1 |
| Steinberg, D | 2 |
| Parthasarathy, S | 1 |
| Carew, TE | 2 |
| Tikkanen, MJ | 1 |
| Nikkilä, EA | 1 |
| Schwenke, DC | 1 |
| Perry, RS | 1 |
| Malinow, MR | 1 |
| Jones, PH | 1 |
| Scott, LW | 1 |
| LaRosa, JC | 1 |
| Iida, H | 1 |
| Izumino, K | 1 |
| Asaka, M | 1 |
| Fujita, M | 1 |
| Nishino, A | 1 |
| Sasayama, S | 1 |
| Graham, I | 1 |
| Ronan, G | 1 |
| Comerford, D | 1 |
| Hickey, N | 1 |
| Daly, L | 1 |
| Mulcahy, R | 1 |
| Feder, D | 1 |
| Langer, AL | 1 |
| Alexandrino, E | 1 |
| Medeiros, S | 1 |
| Lotto, M | 1 |
| Valente, O | 1 |
| Nestruck, AC | 1 |
| Pande, SV | 1 |
| Krishnamurthy, A | 1 |
| Thapar, GS | 1 |
| Shridhar, DR | 1 |
| de Meglio, P | 1 |
| Ravenna, F | 1 |
| Manzardo, S | 1 |
| Gentili, P | 1 |
| Riva, M | 1 |
| Sirtori, C | 1 |
| Fumagalli, R | 1 |
| Paoletti, R | 1 |
| Brown, HB | 1 |
| De Wolfe, VG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effects of Ezetimibe, Simvastatin, and Vytorin on Reducing L5 in Patients With Metabolic Syndrome[NCT00988364] | Phase 4 | 30 participants (Actual) | Interventional | 2007-03-31 | Completed | ||
| Classic Ketogenic Diet and Modified: Evaluation of the Therapeutic Potential and Impact on the Oxidative Profile, Lipidomic, Inflammatory and Size of Lipoproteins in Children and Adolescents With Refractory Epilepsy[NCT02644239] | 60 participants (Anticipated) | Interventional | 2012-06-30 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Patient's blood samples were collected at the corresponding time point for L5 purification. L5 quantification and characterization were investigated with chemical analysis, proteomics and in-vitro cell signaling analysis. Final data analysis will determine total L5 concentration (mg/dL). (NCT00988364)
Timeframe: 3 months
| Intervention | mg/dL (Mean) |
|---|---|
| Ezetimibe | 30.17 |
| Simvastatin | 19.19 |
| Vytorin | 14.17 |
| Placebo | 15.15 |
Patient's blood samples were collected before treatment. L5 were purified by ultracentrifugation then FPLC. Quantification analysis will indicate the L5 concentration (mg/dL) per group. (NCT00988364)
Timeframe: 0 months, at the start
| Intervention | mg/dL (Mean) |
|---|---|
| Ezetimibe | 35.97 |
| Simvastatin | 17.8233 |
| Vytorin | 29.736 |
| Placebo | 23.1 |
30 reviews available for probucol and Hyperlipemia
| Article | Year |
|---|---|
Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients.
Topics: Acids, Acyclic; Area Under Curve; Bile Acids and Salts; Clinical Trials as Topic; Cyclosporine; Drug | 2003 |
Antioxidants, statins, and atherosclerosis.
Topics: Animals; Antioxidants; Ascorbic Acid; beta Carotene; Clinical Trials as Topic; Coronary Artery Disea | 2003 |
Management of hyperlipidaemia associated with heart transplantation.
Topics: Anticholesteremic Agents; Carrier Proteins; Cholesterol, LDL; Fatty Acids, Omega-3; Heart Transplant | 2004 |
[NO and atherosclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antioxidants; Arginine; Arteriosclerosis; Endothe | 2004 |
[Research and developmental strategy of anti-dyslipidemic agents].
Topics: 1-Alkyl-2-acetylglycerophosphocholine Esterase; Animals; Apolipoprotein A-I; Carrier Proteins; Chole | 2007 |
[Animal models for steroid-induced osteonecrosis].
Topics: Animals; Anticholesteremic Agents; Anticoagulants; Disease Models, Animal; Dose-Response Relationshi | 2007 |
[Probucol].
Topics: Anticholesteremic Agents; Humans; Hyperlipidemias; Probucol | 2007 |
[Adverse effects of lipid-lowering medications].
Topics: Anticholesteremic Agents; Arteriosclerosis; Clofibric Acid; Contraindications; Humans; Hydroxymethyl | 2007 |
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl | 1984 |
Hyperlipidemia: perspectives in diagnosis and treatment.
Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Re | 1995 |
Dyslipidemia and coronary artery disease.
Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H | 1994 |
Medical management of hyperlipidemic states.
Topics: Coronary Disease; Diet Therapy; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipoproteins; Pancrea | 1994 |
Trials of the effects of drugs and hormones on lipids and lipoproteins.
Topics: Clinical Trials as Topic; Estrogen Replacement Therapy; Female; Hormones; Human Growth Hormone; Huma | 1995 |
Methods and endpoint issues in clinical development of lipid-acting agents with pleiotropic effects.
Topics: Animals; Clofibrate; Drug Evaluation; Drug Evaluation, Preclinical; Drugs, Investigational; Humans; | 1998 |
[Discrimination between the effects of hypolipidemic and antiatherogenic drugs: probucol pharmacokinetics (review of the literature)].
Topics: Angioplasty, Balloon; Angioplasty, Balloon, Coronary; Animals; Anticholesteremic Agents; Arterioscle | 2000 |
[Probucol].
Topics: Angioplasty, Balloon, Coronary; Animals; Antioxidants; Arteriosclerosis; Clinical Trials as Topic; C | 2001 |
[Nicotinic acid and the derivative].
Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Hum | 2001 |
[Treatments for dyslipidemia associated with kidney disease].
Topics: Anion Exchange Resins; Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibit | 2001 |
[Hyperlipidemia and cerebrovascular disease].
Topics: Anticholesteremic Agents; Apolipoproteins; Cerebral Infarction; Cerebrovascular Disorders; Cholester | 2001 |
Diet and drug synergism in treatment of hypercholesterolemia.
Topics: Adult; Cholesterol, Dietary; Fats, Unsaturated; Female; Humans; Hypercholesterolemia; Hyperlipidemia | 1978 |
Probucol: a review of its pharmacological properties and therapeutic use in patients with hypercholesterolaemia.
Topics: Animals; Arteriosclerosis; Clofibrate; Dogs; Humans; Hypercholesterolemia; Hyperlipidemias; Kinetics | 1978 |
[Therapeutic orientation in the hyperlipidemias].
Topics: Cholestyramine Resin; Dextrothyroxine; Humans; Hypercholesterolemia; Hyperlipidemias; Hypolipidemic | 1979 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1992 |
Management of hyperlipidemia of kidney disease.
Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem | 1990 |
Drug therapy in dyslipidemia.
Topics: Anticholesteremic Agents; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1990 |
[The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Coronary Artery Disease; Humans; Hyperlipi | 1988 |
Reducing cardiac deaths with hypolipidemic drugs.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi | 1987 |
Contemporary recommendations for evaluating and treating hyperlipidemia.
Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lip | 1986 |
The diagnosis and management of hyperlipidemia.
Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr | 1986 |
Hypolipidemic drugs.
Topics: Aminosalicylic Acids; Androgens; Bile Acids and Salts; Butyrates; Cellulose; Cholestyramine Resin; C | 1973 |
19 trials available for probucol and Hyperlipemia
| Article | Year |
|---|---|
Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
Topics: Aged; Anticholesteremic Agents; Antioxidants; Biological Transport; Cardiovascular Diseases; Carotid | 2021 |
Effect of Probucol and/or Cilostazol on Carotid Intima Media Thickness in Patients with Coronary Heart Disease: A Randomized, Multicenter, Multinational Study.
Topics: Anticholesteremic Agents; Carotid Intima-Media Thickness; Cholesterol, HDL; Cholesterol, LDL; Cilost | 2021 |
Effects of atorvastatin versus probucol on low-density lipoprotein subtype distribution and renal function in hyperlipidemic patients with nondiabetic nephropathy.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cross-Over Studies; Female; Heptanoic Acids; Hu | 2010 |
Probucol and ticlopidine: effect on platelet and monocyte activation markers in hyperlipidemic patients with and without type 2 diabetes.
Topics: Aged; Analysis of Variance; Biomarkers; Diabetes Mellitus, Type 2; Drug Therapy, Combination; E-Sele | 2004 |
[Effect of probucol on low-density lipoproteins in patients resistant to diet therapy].
Topics: Adult; Aged; Clinical Trials as Topic; Double-Blind Method; Female; Humans; Hyperlipidemias; Lipopro | 1982 |
Clinical investigation on the hypolipidemic effect of simvastatin versus probucol in hemodialysis patients.
Topics: Aged; Combined Modality Therapy; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Kidney Failu | 1994 |
The effect of probucol and vitamin E treatment on the oxidation of low-density lipoprotein and forearm vascular responses in humans.
Topics: Adult; Cholesterol, LDL; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combinatio | 1994 |
[Effect of probucol on cardiac electrophysiology in anginal patients with hyperlipidemia and diabetes mellitus type II].
Topics: Aged; Angina Pectoris; Anticholesteremic Agents; Biomarkers; Blood Glucose; Body Mass Index; Cardiac | 2000 |
Probucol (Lorelco) in treatment of hyperlipemia.
Topics: Cholesterol; Clinical Trials as Topic; Humans; Hypercholesterolemia; Hyperlipidemias; Lipoproteins, | 1977 |
Diet and probucol in lowering cholesterol concentrations. Additive effects on plasma cholesterol concentrations in patients with familial type ii hyperlipoproteinemia.
Topics: Adult; Cholesterol; Clinical Trials as Topic; Depression, Chemical; Drug Evaluation; Female; Humans; | 1977 |
Effect of probucol in hyperlipidemic patients during two years of administration.
Topics: Adult; Aged; Cholesterol; Clinical Trials as Topic; Female; Humans; Hypercholesterolemia; Hyperlipid | 1978 |
Cholesterol-lowering drugs as cardioprotective agents.
Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA | 1992 |
Pharmacological and dietary treatment of lipid abnormalities in nephrotic patients.
Topics: Cholestyramine Resin; Colestipol; Food, Formulated; Gemfibrozil; Humans; Hyperlipidemias; Lipids; Lo | 1991 |
Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with alpha-tocopheryl nicotinate.
Topics: Adult; Aged; Apolipoprotein C-II; Apolipoproteins C; Cholesterol; Cholesterol, HDL; Female; Humans; | 1990 |
A multicenter comparison of lovastatin and probucol for treatment of severe primary hypercholesterolemia. The Lovastatin Study Group IV.
Topics: Adult; Aged; Apolipoproteins; Cholesterol; Cholesterol, LDL; Double-Blind Method; Drug Evaluation; F | 1990 |
Comparative study of bezafibrate and probucol in hyperlipidaemia.
Topics: Adult; Aged; Bezafibrate; Clinical Trials as Topic; Dietary Fats; Female; Humans; Hyperlipidemias; M | 1989 |
Long-term use of probucol in the multifactorial primary prevention of vascular disease.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Cerebrovascular Disorders; Cholesterol, HDL; C | 1986 |
[The value of chemotherapeutic intervention on primary hyperlipidemias in the prevention of coronary arteriosclerosis].
Topics: Adult; Cholesterol; Clinical Trials as Topic; Colestipol; Coronary Artery Disease; Humans; Hyperlipi | 1988 |
The additive effect of probucol on diet in hyperlipidemia.
Topics: Adult; Aged; Anticholesteremic Agents; Body Weight; Cholesterol; Clinical Trials as Topic; Diet Ther | 1974 |
76 other studies available for probucol and Hyperlipemia
| Article | Year |
|---|---|
Novel benzoxazine and benzothiazine derivatives as multifunctional antihyperlipidemic agents.
Topics: Animals; Antioxidants; Atherosclerosis; Benzoxazines; Cholesterol, LDL; Farnesyl-Diphosphate Farnesy | 2011 |
New multifunctional Di-tert-butylphenoloctahydro(pyrido/benz)oxazine derivatives with antioxidant, antihyperlipidemic, and antidiabetic action.
Topics: Animals; Antioxidants; Atherosclerosis; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mel | 2013 |
New Horizons for Probucol, an Old, Mysterious Drug.
Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clinical Tria | 2021 |
Study on the Mechanism of Probucol Nanosuspension on Hyperlipidemic Pancreatitis and Regulation of Blood Lipid Function.
Topics: Acute Disease; Humans; Hyperlipidemias; Lipids; Pancreatitis; Probucol | 2021 |
Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Caco-2 Cells; Cholesterol; Dendrimers; Drug | 2015 |
The Heart Protection Effect of Alcalase Potato Protein Hydrolysate Is through IGF1R-PI3K-Akt Compensatory Reactivation in Aging Rats on High Fat Diets.
Topics: Aging; Animals; Anticholesteremic Agents; Apoptosis; Cardiotonic Agents; Cholesterol; Diet, High-Fat | 2015 |
Probucol inhibits LPS-induced microglia activation and ameliorates brain ischemic injury in normal and hyperlipidemic mice.
Topics: Animals; Apolipoproteins E; Brain Ischemia; Diet, High-Fat; Dinoprostone; Dose-Response Relationship | 2016 |
Effects of probucol in hyperlipidemic rabbit liver: a preliminary ultrastructural study.
Topics: Animals; Anticholesteremic Agents; Endoplasmic Reticulum; Female; Hyperlipidemias; Liver; Male; Micr | 2002 |
The effect of probucol on atherosclerosis in streptozotocin-induced diabetic-hyperlipidemic APA hamsters in different stages of atherosclerosis.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Cricetinae; D | 2002 |
Anthocyanins increase low-density lipoprotein and plasma cholesterol and do not reduce atherosclerosis in Watanabe Heritable Hyperlipidemic rabbits.
Topics: Animals; Anthocyanins; Aorta; Arteriosclerosis; Beverages; Cholesterol; Cholesterol, VLDL; Diet; Ery | 2005 |
Reduction of oxidative stress and atherosclerosis in hyperlipidemic rabbits by Dioscorea rhizome.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Atherosclerosis; Catalase; Dietary | 2005 |
Reduction of oxidative stress and apoptosis in hyperlipidemic rabbits by ellagic acid.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Anticholesteremic Agents; Antioxidants; Aorta, Thoracic; Apopt | 2005 |
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil | 1983 |
Hyperlipidemia: reducing the chances of cardiovascular disease.
Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Coronary Disease; Gemfibrozil; Humans; Hyperlipidemia | 1984 |
Pharmacologic therapy for the hyperlipidemic patient.
Topics: Bile Acids and Salts; Clofibrate; Dextrothyroxine; Humans; Hyperlipidemias; Hypolipidemic Agents; Ni | 1983 |
Effects of probucol on lipoprotein protein kinetics.
Topics: Apolipoproteins; Bile Acids and Salts; Cholesterol; Humans; Hyperlipidemias; Kinetics; Lipoproteins; | 1982 |
One year experience with probucol, a new hypocholesterolaemic agent.
Topics: Adult; Cholesterol; Female; Humans; Hyperlipidemias; Male; Middle Aged; Phenols; Probucol; Triglycer | 1982 |
[Free and esterified cholesterol of the skin in atherogenic hyperlipidemias].
Topics: Aged; Cholesterol; Cholesterol Esters; Female; Humans; Hyperlipidemias; Male; Middle Aged; Probucol; | 1981 |
[Evaluation of the effect of probucol on blood lipids].
Topics: Adult; Aged; Cholesterol; Female; Humans; Hyperlipidemias; Male; Middle Aged; Phenols; Probucol; Tri | 1981 |
Drug treatment of hyperlipidemia.
Topics: Adolescent; Adult; Child; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hyperli | 1980 |
[Probuscol (Lurselle)].
Topics: Animals; Humans; Hyperlipidemias; Phenols; Probucol | 1980 |
[Hypolipidaemic agents (author's transl)].
Topics: Animals; Chemical Phenomena; Chemistry; Cholesterol; Cholestyramine Resin; Clofibrate; Humans; Hyper | 1980 |
Effect of a lipid-lowering agent or a high-cholesterol diet on focal glomerulosclerosis in hyperlipidemic rats.
Topics: Animals; Body Weight; Cholesterol; Cholesterol, Dietary; Glomerulosclerosis, Focal Segmental; Hyperl | 1995 |
Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Dose-Response Relationship, Drug; Hyperlipidemias; Lipid Peroxides | 1994 |
[The effect of long-term probucol intake on the lipoprotein cholesterol content and glutathione peroxidase activity in the blood of patients with coronary arteriosclerosis and hyperlipidemia].
Topics: Cholesterol, HDL; Cholesterol, LDL; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Femal | 1993 |
Indications for the presence of circulating peroxidized low density lipoproteins in WHHL rabbits treated with antioxidants.
Topics: Animals; Antioxidants; Apolipoprotein B-100; Apolipoproteins B; Hyperlipidemias; Lipid Peroxidation; | 1993 |
Positive correlation between probucol in low density lipoprotein and LDL-lowering.
Topics: Adult; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Lipoprotein | 1993 |
Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association.
Topics: Cholesterol, Dietary; Coronary Disease; Diet; Fatty Acids, Omega-3; Female; Humans; Hyperlipidemias; | 1993 |
Protective aspects for atherogenesis and lipid abnormalities in continuous ambulatory peritoneal dialysis patients.
Topics: Aged; Aged, 80 and over; Arteriosclerosis; Creatinine; Female; Glutathione Peroxidase; Humans; Hyper | 1993 |
Probucol reduces hepatic cholesterol secretion in hyperlipidemic Yoshida rats.
Topics: Animals; Anticholesteremic Agents; Bile; Body Weight; Cholesterol; Cholesterol Esters; Cholesterol, | 1996 |
Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation.
Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Echocardiography; Fem | 1997 |
Long-term probucol treatment reverses the severity of myocardial injury in watanabe heritable hyperlipidemic rabbits.
Topics: Administration, Oral; Animals; Antioxidants; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; Cor | 1997 |
[The antioxidant probucol as a regulator of the intensity of free-radical lipid peroxidation processes in the blood of patients with coronary atherosclerosis].
Topics: Antioxidants; Chronic Disease; Coronary Artery Disease; Drug Evaluation; Female; Free Radicals; Glut | 1997 |
The effect of probucol on intimal thickening of autologous vein grafts in hyperlipidemic rabbit.
Topics: Animals; Anticholesteremic Agents; Blood Vessel Prosthesis; Blood Vessel Prosthesis Implantation; Fe | 1997 |
Probucol treatment attenuates the aortic atherosclerosis in Watanabe heritable hyperlipidemic rabbits.
Topics: Actins; Animals; Anticholesteremic Agents; Aorta, Abdominal; Aorta, Thoracic; Aortic Diseases; Arter | 1998 |
Survival and cardiovascular pathology of heterozygous Watanabe heritable hyperlipidaemic rabbits treated with pravastatin and probucol on a low-cholesterol (0.03%)-enriched diet.
Topics: Animals; Aorta; Cholesterol; Cholesterol, Dietary; Coronary Artery Disease; Drug Therapy, Combinatio | 1998 |
Lipid lowering therapy in the treatment of lower limb atherosclerosis.
Topics: Anticholesteremic Agents; Arteriosclerosis; Clinical Trials as Topic; Data Collection; Databases, Bi | 1998 |
Probucol selectively increases oxidation of atherogenic lipoproteins in cholesterol-fed mice and in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, Dietary; Hyperlipidem | 1999 |
Probucol for treatment of hyperlipidemia in persistent childhood nephrotic syndrome. Report of a prospective uncontrolled multicenter study.
Topics: Adolescent; Adult; Anticholesteremic Agents; Child; Child, Preschool; Electrocardiography; Glomerula | 1999 |
Dissociation of atherogenesis from aortic accumulation of lipid hydro(pero)xides in Watanabe heritable hyperlipidemic rabbits.
Topics: Animals; Aorta; Arteriosclerosis; Hyperlipidemias; Lipid Peroxidation; Lipids; Lipoproteins, LDL; Ma | 1999 |
Noninvasive 3-D ultrasound of atherosclerotic plaques in the Watanabe rabbit.
Topics: Algorithms; Animals; Anticholesteremic Agents; Aorta, Thoracic; Aortic Diseases; Arteriosclerosis; F | 1999 |
Lysophosphatidylcholine molecular species in low density lipoprotein and high density lipoprotein in alloxan-induced diabetic rats: effect of probucol.
Topics: Animals; Anticholesteremic Agents; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Hyp | 1999 |
The effect of vitamin E, probucol, and lovastatin on oxidative status and aortic fatty lesions in hyperlipidemic-diabetic hamsters.
Topics: Animals; Animals, Newborn; Anticholesteremic Agents; Antioxidants; Arteriosclerosis; Cells, Cultured | 2000 |
Syntheses and biological evaluation of 3-substituted amino-1-aryl-6-hydroxy-hex-2-ene-1-ones as antioxidant and hypolipidemic agents.
Topics: Alkenes; Animals; Antioxidants; Cholesterol; Cholesterol, LDL; Commiphora; Copper; Ethylamines; Hype | 2000 |
The effect of pharmacological doses of different antioxidants on oxidation parameters and atherogenesis in hyperlipidaemic rabbits.
Topics: Administration, Oral; Animals; Anticholesteremic Agents; Antidotes; Antioxidants; Aorta; Arterioscle | 2001 |
[Effect of probucol on the concentration of cyclosporin A in patients with nephrotic syndrome].
Topics: Adult; Aged; Anticholesteremic Agents; Cyclosporine; Drug Interactions; Drug Therapy, Combination; F | 2001 |
Hypolipidemic drugs.
Topics: Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyroxine; Humans; Hyperlipidemias; Lipoproteins | 1978 |
Treatment of hyperlipoproteinemias with neomycin, probucol and tibric acid.
Topics: Cholesterol; Feces; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid Metabolism; Neomycin; Pheno | 1977 |
[Treatment of hyperlipidemia].
Topics: Blood Component Removal; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Dieta | 1992 |
Probucol reduces plasma lipid peroxides in man.
Topics: Adult; Cholesterol; Humans; Hyperlipidemias; Lipid Peroxides; Male; Middle Aged; Probucol; Vitamin E | 1992 |
[Clinical study of lipid metabolism disorders (discussion)].
Topics: Arteriosclerosis; Cholestyramine Resin; Diet; Humans; Hyperlipidemias; Lipid Metabolism; Lovastatin; | 1992 |
Treatment of hyperlipidemia with probucol suppresses the development of focal and segmental glomerulosclerosis in chronic aminonucleoside nephrosis.
Topics: Animals; Glomerulosclerosis, Focal Segmental; Hyperlipidemias; Male; Nephrotic Syndrome; Probucol; P | 1992 |
Probucol and atherosclerosis in the Watanabe heritable hyperlipidemic rabbit--long-term antiatherogenic effect and effects on established plaques.
Topics: Animals; Aorta; Arteriosclerosis; Cholesterol; Female; Hyperlipidemias; Lipids; Male; Probucol; Rabb | 1992 |
Post-marketing surveillance of probucol (Sinlestal) in Japan.
Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Electrocardiography; Female; Humans; Hyperlipidemias; Hy | 1992 |
[Hyperlipidemia and drug treatment].
Topics: Arteriosclerosis; Carnitine; Cholestyramine Resin; Glomerulonephritis; Humans; Hyperlipidemias; Kidn | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
Some questions concerning a small, more electronegative LDL circulating in human plasma.
Topics: Animals; Arteriosclerosis; Artifacts; Chromatography, High Pressure Liquid; Chromatography, Ion Exch | 1991 |
The lowering effect of probucol on plasma lipoprotein and proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Hyperlipoproteinemias; Kidney; Male; Nephrotic Syndrome; Organ Size; Probu | 1991 |
The effects of probucol on the progression of atherosclerosis in mature Watanabe heritable hyperlipidaemic rabbits.
Topics: Animals; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipids; Lipoproteins, LDL; Oxidation-Reduct | 1991 |
Antiatherosclerotic effect of probucol in WHHL rabbits: are there plasma parameters to evaluate this effect?
Topics: Animals; Antioxidants; Arteriosclerosis; Female; Hyperlipidemias; Lipid Peroxidation; Male; Probucol | 1991 |
Mechanisms of low density lipoprotein lowering by hypolipidemic agents.
Topics: Carrier Proteins; Cholesterol Ester Transfer Proteins; Estrogens; Female; Glycoproteins; Humans; Hyd | 1991 |
Treatment of hyperlipidemia with probucol reduces proteinuria in puromycin aminonucleoside-induced nephrotic rats.
Topics: Animals; Hyperlipidemias; Male; Nephrotic Syndrome; Phenols; Probucol; Proteinuria; Puromycin Aminon | 1990 |
Hypercoagulable state in the Watanabe heritable hyperlipidemic rabbit, an animal model for the progression of atherosclerosis. Effect of probucol on coagulation.
Topics: Aging; Animals; Arteriosclerosis; Blood Coagulation Factors; Disease Models, Animal; Hyperlipidemias | 1989 |
Prevention of atherosclerotic progression in Watanabe rabbits by probucol.
Topics: Animals; Arteriosclerosis; Cells, Cultured; Drug Evaluation, Preclinical; Female; Foam Cells; Hyperl | 1988 |
In vivo inhibition of foam cell development by probucol in Watanabe rabbits.
Topics: Animals; Arteriosclerosis; Depression, Chemical; Drug Evaluation, Preclinical; Foam Cells; Hyperlipi | 1988 |
Medical management of hyperlipidemia and the role of probucol.
Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem | 1986 |
Current pharmacologic treatment of elevated serum cholesterol.
Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co | 1987 |
Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in
Topics: Animals; Antioxidants; Aorta; Arteriosclerosis; Cholesterol; Hyperlipidemias; Lipoproteins, LDL; Lov | 1987 |
Adverse effects of the treatment for hyperlipidemia.
Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug The | 1986 |
Drug therapy for lipid disorders. Selecting appropriate lipid-lowering agents.
Topics: Anticholesteremic Agents; Cholesterol; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyper | 1987 |
Effect of probucol on hyperlipidemia in patients with nephrotic syndrome.
Topics: Adult; Cholesterol; Female; Humans; Hyperlipidemias; Lipoproteins, HDL; Lipoproteins, LDL; Male; Mid | 1987 |
A symposium: New developments in the treatment of hypercholesterolemia--probucol. December 7, 1985, New York, New York.
Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Phenols; Probucol | 1986 |
Probucol, blood lipids and the ECG QTc interval.
Topics: Adult; Aged; Electrocardiography; Female; Humans; Hyperlipidemias; Lipids; Lipoproteins; Male; Middl | 1986 |
[Probucol in the treatment of hyperlipidemias].
Topics: Animals; Cholesterol; Humans; Hyperlipidemias; Phenols; Probucol; Rabbits; Rats; Triglycerides | 1986 |
Plasma carnitine and lipid-lowering drugs.
Topics: Carnitine; Cholesterol, HDL; Clofibrate; Female; Humans; Hyperlipidemia, Familial Combined; Hyperlip | 1985 |
Effect of probucol on triton induced hyperlipidemias in CFY rats.
Topics: Animals; Cholesterol; Clofibrate; Hyperlipidemias; Hypolipidemic Agents; Male; Phenols; Polyethylene | 1985 |
[New derivatives of clofibrate and probucol. Preliminary study of their hypolipemic activity].
Topics: Animals; Chemical Phenomena; Chemistry; Clofibrate; Hyperlipidemias; Hypolipidemic Agents; Male; Mic | 1985 |